Atomo Diagnostics (AT1) 2023年年度报告「ASX」.pdf

1、Annual Report2023Empowering healthcare consumersAtomo Diagnostics LimitedACN 142 925 Who we are1Chairmans letter2 CEOs Report4Delivering on our strategy6 Key Metrics7Rapidly Growing Markets8Operational Capabilities13ESG14People&Culture15Directors Report18Financial Statements34Statement of Profit or

2、Loss and Other Comprehensive Income35Statement of Financial Position36Statement of Changes in Equity37Statement of Cash Flows38Notes to Financial Statements39Directors Declaration66Independent Auditors Report67Shareholder Information71Corporate Directory73ATOMO ANNUAL REPORT 2023ATOMO ANNUAL REPORT

3、20231Empowering people to enjoy healthier,more informed lives through fast,accurate Point-of-Care testing.We are re-imagining diagnostics by putting the user experience at the centre of everything we do.Atomos mission is to ensure equitable and affordable access to accurate diagnoses and promote a s

4、eamless pathway to treatment.Point-of-Care Test ProductsHIV,pregnancy and iron deficiency(ferritin)tests for Point-of-Care and at-home self-test,distributed through an expanding global network,with more clinical applications to come.Point-of-Care Test Platform TechnologyUnique blood and swab test de

5、vices and components,sold to partners with capability to incorporate other indications.Who we areWe are an innovative medical device diagnostics company supplying unique,integrated rapid diagnostic test devices and finished Point-of-Care rapid tests to global partners and consumers.Atomos strategic

6、focus is on two revenue generators:ATOMO ANNUAL REPORT 20232Chairmans LetterDear Shareholders,I write to thank you for your continuing support of Atomo Diagnostics(Atomo),and to introduce our Annual Report to June 30,2023.Throughout the year,we saw continuing consumer and professional user adoption